ZP SPV 3 K/S: Financial statements 2023
CVR: 41038039
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
ZP SPV 3 K/S (CVR 41038039) has filed annual accounts for 2023. In 2023, the company reported revenue of DKK 7,448,000 and a net result of DKK 1,061,000 compared with DKK -1,791,000 the year before. That is a decrease of 80.3% compared with the year before. The profit margin was 14.2%. Equity in the 2023 report amounted to DKK 36,235,000. The solvency ratio was 79.9%.
- Revenue
- DKK 7,448,000
- Gross Profit
- DKK 7,448,000
- Profit/Loss
- DKK 1,061,000
- Equity
- DKK 36,235,000
- Total Assets
- DKK 45,374,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 7.4M | 7.4M | 1.1M | 36.2M | - |
| 2022 | 37.8M | 37.8M | -1.8M | 35.2M | - |
| 2021 | 1.6M USD | 1.6M USD | 50K USD | 5.6M USD | - |
| 2020 | 1K USD | 1K USD | -118 USD | 6K USD | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
ZP SPV 3 K/S has published its annual report for 2022. Revenue came to DKK 37,755,000, and the net result was DKK -1,791,000.
About ZP SPV 3 K/S
ZP SPV 3 K/S is a Danish company of the type Kommanditselskab based in Søborg, founded in 2019. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of ZP General Partner 3 ApS. The company is owned by ZEALAND PHARMA A/S. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -1,039,000 compared with DKK -34,739,000 the year before. Equity in the 2025 report amounted to DKK 429,000.
